Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Abstract
Biomarkers for the prediction of cognitive decline in patients with amnestic mild cognitive impairment (MCI) and amnestic mild dementia are needed for both clinical practice and clinical trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 14, 2022
- Source ID
- 10.1002/alz.12875
Entities
People
- Alexa Pichet Binette
- Antoine Leuzy
- Edilio Borroni
- Erik Stomrud
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Gregory Klein
- Henrik Zetterberg
- Kaj Blennow
- Nicholas C. Cullen
- Niklas Mattsson‐carlgren
- Oskar Hansson
- Rik Ossenkoppele
- Ruben Smith
- Sebastian Palmqvist
- Shorena Janelidze
Organizations
- European Research Council
- Familjen Erling-Perssons Stiftelse
- Hjärnfonden
- Hoffmann-La Roche
- Knut and Alice Wallenberg Foundation
- Lund University
- National Institutes of Health
- Sahlgrenska University Hospital
- Skåne University Hospital
- Stiftelsen Gamla Tjänarinnor
- Swedish Research Council
- United States Department of Defense
- University College London
- Vrije Universiteit Amsterdam